Explore Bayer
Core profile pages, annual revenue records, and related research hubs for this company.
Explore Bayer
Core profile pages, annual revenue records, and related research hubs for this company.
Business Model Analysis
Annual Revenue: $49.5B
Bayer's business model combines regulated prescription medicines, over-the-counter consumer health brands, and agricultural inputs. Pharmaceuticals sells prescription products and earns licensing income; Consumer Health sells self-care brands through retail and pharmacy channels; Crop Science sells seeds, traits, herbicides, fungicides, insecticides, and digital agriculture solutions to growers and distributors.
The growth strategy centers on Nubeqa and Kerendia in Pharmaceuticals, selective Consumer Health brand investment, crop-science portfolio discipline, lower organizational complexity, and cash generation directed toward debt reduction.
Bayer makes money from prescription medicines, consumer self-care products, seeds, traits, herbicides, fungicides, insecticides, and digital agriculture tools.
Bayer serves patients, clinicians, pharmacies, health systems, consumers, growers, crop retailers, and agricultural distributors.
The largest revenue driver is the Crop Science division, while Pharmaceuticals carries the highest strategic importance for long-term margin recovery.
Its durability comes from regulated medicine franchises, global brands, seed germplasm, farmer relationships, and scale across more than 80 countries.
Bayer's biggest risk is the combined pressure of Roundup litigation, net financial debt, crop-chemical price competition, and Xarelto patent erosion.